- Home
- KYMR
as 03-25-2025 10:38am EST
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 2.2B | IPO Year: | 2020 |
| Target Price: | $56.69 | AVG Volume (30 days): | 748.6K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $29.07 - $53.27 | Next Earning Date: | 05-01-2025 |
| Revenue: | $47,072,000 | Revenue Growth: | -40.11% |
| Revenue Growth (this year): | 44.93% | Revenue Growth (next year): | -2.18% |
Stock Insider Trading Activity of Kymera Therapeutics Inc. (KYMR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gollob Jared | KYMR | Chief Medical Officer | Mar 3 '25 | Sell | $30.67 | 5,740 | $174,785.54 | 121,045 | |
| Chiniara Ellen | KYMR | Chief Legal Officer | Mar 3 '25 | Sell | $30.67 | 2,241 | $68,239.45 | 80,085 | |
| Jacobs Bruce N. | KYMR | Chief Financial Officer | Mar 3 '25 | Sell | $30.67 | 7,035 | $214,219.03 | 203,167 | |
| Chadwick Jeremy G | KYMR | Chief Operating Officer | Mar 3 '25 | Sell | $30.67 | 1,383 | $42,113.11 | 67,800 | |
| Chiniara Ellen | KYMR | Chief Legal Officer | Jan 6 '25 | Sell | $41.75 | 3,129 | $130,644.82 | 80,085 |
Latest Kymera Therapeutics Inc. News
KYMR Breaking Stock News: Dive into KYMR Ticker-Specific Updates for Smart Investing
MT Newswires
13 days ago
Citigroup Initiates Coverage on Kymera Therapeutics With Buy Rating, $52 Price Target
Simply Wall St.
20 days ago
Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook
Simply Wall St.
25 days ago
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates
Zacks
a month ago
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
Simply Wall St.
a month ago
We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate
GuruFocus.com
a month ago
Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...
MT Newswires
a month ago
Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls
Zacks
a month ago
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
Compare KYMR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KYMR Kymera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.